RYOAX — Biotechnology Fund
Data updated: 2026-06-15
RYOAX — Biotechnology Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $135.07M AUM · 1.65% expense ratio · 34.9% 1-yr return. From SEC regulatory filings.
RYOAX Fund Overview
RYOAX — Biotechnology Fund is a US mutual fund managed by Rydex Series Funds, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Rydex Series Funds
- Category: United States Health Care Equity
- Assets under management: $135.07M
- 1-year return: 34.9%
- Ticker: RYOAX
- SEC CIK: 0000899148
- SEC series ID: S000003802
- Share class ID: C000010595
RYOAX Holdings
Top 10 holdings of Biotechnology Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| AbbVie Inc. | 7.39% |
| Amgen Inc. | 5.23% |
| Gilead Sciences Inc. | 4.96% |
| Vertex Pharmaceuticals Incorporated | 4.01% |
| Regeneron Pharmaceuticals, Inc. | 3.56% |
| Alnylam Pharmaceuticals Inc. | 2.60% |
| Insmed Inc | 2.45% |
| Beone Medicines Ltd. | 2.29% |
| Natera, Inc. | 2.09% |
| United Therapeutics Corporation | 2.07% |
RYOAX Portfolio Allocation
Asset-class allocation of Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 98.7% |
| Cash & Equivalents | 0.4% |
RYOAX Performance
Total returns for RYOAX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 2.0% |
| 1 year | 34.9% |
| 3 years (annualised) | 12.5% |
| 5 years (annualised) | 4.5% |
RYOAX Risk Information
Risk metrics for RYOAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.8%
RYOAX Costs and Fees
RYOAX costs about $165 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.65%
- Gross expense ratio: 1.68%
- Portfolio turnover: 51%
- Brokerage commissions: 2.49 bps of average net assets (SEC N-CEN)
RYOAX Cashflows
Over the 12 months to 2026-03, Biotechnology Fund had net inflows of $32.12M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$189.18K |
| 2026-02 | −$772.29K |
| 2026-01 | $24.75M |
| 2025-12 | $6.69M |
| 2025-11 | $8.99M |
| 2025-10 | $1.93M |
RYOAX Debt Constituents
No individual debt constituents are reported in Biotechnology Fund's latest SEC N-PORT filing.
RYOAX Prospectus and SEC Filings
Official Biotechnology Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.